Join
Live feed
·
PRReleasevia Quantisnow
Praxis Precision Medicines Inc. logo

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

ByQuantisnow·Wall Street's wire, on your screen.
PRAX· Praxis Precision Medicines Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRAX (Praxis Precision Medicines Inc.) and more on Quantisnow.